vs
APOGEE ENTERPRISES, INC.（APOG）とPrestige Consumer Healthcare Inc.（PBH）の財務データ比較。上の社名をクリックして会社を切り替えられます
APOGEE ENTERPRISES, INC.の直近四半期売上が大きい（$351.4M vs $283.4M、Prestige Consumer Healthcare Inc.の約1.2倍）。Prestige Consumer Healthcare Inc.の純利益率が高く（16.5% vs 4.7%、差は11.7%）。APOGEE ENTERPRISES, INC.の前年同期比売上増加率が高い（1.6% vs -2.4%）。過去8四半期でAPOGEE ENTERPRISES, INC.の売上複合成長率が高い（2.9% vs 1.2%）
Apogee Enterprisesはアメリカのオーディオ機器メーカーです。オーディオインターフェース、AD/DAコンバーター、USB・iOS対応マイクの製造を主軸に、オーディオ制作向けソフトウェアの開発も手がけており、プロの録音や音楽制作分野で広く利用されています。
プレステージ・コンシューマー・ヘルスケア社はアメリカの企業で、一般用医薬品のヘルスケア製品および家庭用洗浄製品の販売・流通を手がけています。1996年にMedtech Products社、Prestige Brands International社、Spic and Span社の合併により設立され、本社はニューヨーク州タリータウン、バージニア州リンチバーグに製造工場を構えています。
APOG vs PBH — 直接比較
損益計算書 — Q4 FY2026 vs Q3 FY2026
| 指標 | | |
|---|---|---|
| 売上 | $351.4M | $283.4M |
| 純利益 | $16.6M | $46.7M |
| 粗利率 | 22.4% | 55.5% |
| 営業利益率 | 7.3% | 29.1% |
| 純利益率 | 4.7% | 16.5% |
| 売上前年比 | 1.6% | -2.4% |
| 純利益前年比 | 568.8% | -23.5% |
| EPS（希薄化後） | $0.78 | $0.97 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q1 26 | $351.4M | — | ||
| Q4 25 | $348.6M | $283.4M | ||
| Q3 25 | $358.2M | $274.1M | ||
| Q2 25 | $346.6M | $249.5M | ||
| Q1 25 | $345.7M | $296.5M | ||
| Q4 24 | $341.3M | $290.3M | ||
| Q3 24 | $342.4M | $283.8M | ||
| Q2 24 | $331.5M | $267.1M |
| Q1 26 | $16.6M | — | ||
| Q4 25 | $16.5M | $46.7M | ||
| Q3 25 | $23.6M | $42.2M | ||
| Q2 25 | $-2.7M | $47.5M | ||
| Q1 25 | $2.5M | $50.1M | ||
| Q4 24 | $21.0M | $61.0M | ||
| Q3 24 | $30.6M | $54.4M | ||
| Q2 24 | $31.0M | $49.1M |
| Q1 26 | 22.4% | — | ||
| Q4 25 | 23.8% | 55.5% | ||
| Q3 25 | 23.1% | 55.3% | ||
| Q2 25 | 21.7% | 56.2% | ||
| Q1 25 | 21.6% | 57.3% | ||
| Q4 24 | 26.1% | 55.5% | ||
| Q3 24 | 28.4% | 55.5% | ||
| Q2 24 | 29.8% | 54.7% |
| Q1 26 | 7.3% | — | ||
| Q4 25 | 7.1% | 29.1% | ||
| Q3 25 | 7.5% | 29.1% | ||
| Q2 25 | 2.0% | 28.8% | ||
| Q1 25 | 1.8% | 29.8% | ||
| Q4 24 | 8.4% | 31.7% | ||
| Q3 24 | 12.3% | 29.7% | ||
| Q2 24 | 12.5% | 27.0% |
| Q1 26 | 4.7% | — | ||
| Q4 25 | 4.7% | 16.5% | ||
| Q3 25 | 6.6% | 15.4% | ||
| Q2 25 | -0.8% | 19.0% | ||
| Q1 25 | 0.7% | 16.9% | ||
| Q4 24 | 6.1% | 21.0% | ||
| Q3 24 | 8.9% | 19.2% | ||
| Q2 24 | 9.4% | 18.4% |
| Q1 26 | $0.78 | — | ||
| Q4 25 | $0.77 | $0.97 | ||
| Q3 25 | $1.10 | $0.86 | ||
| Q2 25 | $-0.13 | $0.95 | ||
| Q1 25 | $0.12 | $1.00 | ||
| Q4 24 | $0.96 | $1.22 | ||
| Q3 24 | $1.40 | $1.09 | ||
| Q2 24 | $1.41 | $0.98 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $39.5M | $62.4M |
| 総負債低いほど良い | $232.3M | $1.0B |
| 株主資本純資産 | $511.8M | $1.8B |
| 総資産 | $1.1B | $3.5B |
| 負債/資本比率低いほどレバレッジが低い | 0.45× | 0.56× |
8四半期トレンド — 暦四半期で整列
| Q1 26 | $39.5M | — | ||
| Q4 25 | $41.3M | $62.4M | ||
| Q3 25 | $39.5M | $119.1M | ||
| Q2 25 | $32.8M | $139.5M | ||
| Q1 25 | $41.4M | $97.9M | ||
| Q4 24 | $43.9M | $50.9M | ||
| Q3 24 | $51.0M | $51.5M | ||
| Q2 24 | $30.4M | $34.3M |
| Q1 26 | $232.3M | — | ||
| Q4 25 | — | $1.0B | ||
| Q3 25 | — | $993.1M | ||
| Q2 25 | — | $992.7M | ||
| Q1 25 | $285.0M | $992.4M | ||
| Q4 24 | — | $992.0M | ||
| Q3 24 | — | $1.1B | ||
| Q2 24 | — | $1.1B |
| Q1 26 | $511.8M | — | ||
| Q4 25 | $512.3M | $1.8B | ||
| Q3 25 | $500.2M | $1.8B | ||
| Q2 25 | $481.8M | $1.9B | ||
| Q1 25 | $487.9M | $1.8B | ||
| Q4 24 | $522.1M | $1.8B | ||
| Q3 24 | $506.4M | $1.7B | ||
| Q2 24 | $480.0M | $1.7B |
| Q1 26 | $1.1B | — | ||
| Q4 25 | $1.1B | $3.5B | ||
| Q3 25 | $1.2B | $3.4B | ||
| Q2 25 | $1.2B | $3.4B | ||
| Q1 25 | $1.2B | $3.4B | ||
| Q4 24 | $1.2B | $3.3B | ||
| Q3 24 | $917.1M | $3.3B | ||
| Q2 24 | $889.0M | $3.3B |
| Q1 26 | 0.45× | — | ||
| Q4 25 | — | 0.56× | ||
| Q3 25 | — | 0.54× | ||
| Q2 25 | — | 0.54× | ||
| Q1 25 | 0.58× | 0.54× | ||
| Q4 24 | — | 0.55× | ||
| Q3 24 | — | 0.61× | ||
| Q2 24 | — | 0.65× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $122.5M | $78.3M |
| フリーキャッシュフロー営業CF - 設備投資 | — | $75.3M |
| FCFマージンFCF / 売上 | — | 26.6% |
| 設備投資強度設備投資 / 売上 | 7.8% | 1.1% |
| キャッシュ転換率営業CF / 純利益 | 7.37× | 1.68× |
| 直近12ヶ月FCF直近4四半期 | — | $267.2M |
8四半期トレンド — 暦四半期で整列
| Q1 26 | $122.5M | — | ||
| Q4 25 | $29.3M | $78.3M | ||
| Q3 25 | $57.1M | $57.5M | ||
| Q2 25 | $-19.8M | $79.0M | ||
| Q1 25 | $30.0M | $61.8M | ||
| Q4 24 | $31.0M | $65.1M | ||
| Q3 24 | $58.7M | $69.8M | ||
| Q2 24 | $5.5M | $54.8M |
| Q1 26 | — | — | ||
| Q4 25 | $22.9M | $75.3M | ||
| Q3 25 | $52.4M | $55.4M | ||
| Q2 25 | $-26.9M | $78.2M | ||
| Q1 25 | $19.1M | $58.4M | ||
| Q4 24 | $22.0M | $63.5M | ||
| Q3 24 | $50.2M | $67.8M | ||
| Q2 24 | $-1.8M | $53.6M |
| Q1 26 | — | — | ||
| Q4 25 | 6.6% | 26.6% | ||
| Q3 25 | 14.6% | 20.2% | ||
| Q2 25 | -7.8% | 31.3% | ||
| Q1 25 | 5.5% | 19.7% | ||
| Q4 24 | 6.4% | 21.9% | ||
| Q3 24 | 14.7% | 23.9% | ||
| Q2 24 | -0.5% | 20.1% |
| Q1 26 | 7.8% | — | ||
| Q4 25 | 1.9% | 1.1% | ||
| Q3 25 | 1.3% | 0.8% | ||
| Q2 25 | 2.1% | 0.3% | ||
| Q1 25 | 3.2% | 1.2% | ||
| Q4 24 | 2.6% | 0.5% | ||
| Q3 24 | 2.5% | 0.7% | ||
| Q2 24 | 2.2% | 0.4% |
| Q1 26 | 7.37× | — | ||
| Q4 25 | 1.77× | 1.68× | ||
| Q3 25 | 2.41× | 1.36× | ||
| Q2 25 | — | 1.66× | ||
| Q1 25 | 12.08× | 1.23× | ||
| Q4 24 | 1.48× | 1.07× | ||
| Q3 24 | 1.92× | 1.28× | ||
| Q2 24 | 0.18× | 1.12× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
APOG
| Architectural Services | $127.1M | 36% |
| Architectural Metals | $110.0M | 31% |
| Architectural Glass | $67.4M | 19% |
| Performance Surfaces | $54.3M | 15% |
PBH
| Womens Health | $51.8M | 18% |
| International OTC Healthcare | $47.7M | 17% |
| Gastrointestinal | $44.2M | 16% |
| Eye And Ear Care | $35.2M | 12% |
| Dermatologicals | $27.6M | 10% |
| Analgesics | $26.7M | 9% |
| Oral Care | $23.5M | 8% |
| Cough And Cold | $23.0M | 8% |
| Other Otc | $3.6M | 1% |
